TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39642315
Drug: Fitusiran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran (50 mg or 80 mg)
Study: 39642315
Drug: Fitusiran (AT-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran (AT-based dose regimen)
Study: 39642783
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Therapy with financial incentives (PE+)
Study: 39644535
Drug: HAI-FUDR (Hepatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI-FUDR (Hepatic Arterial Infusion of Floxuridine)
Study: 39644535
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic chemotherapy only (non-HAI group)
Study: 39644858
Drug: Aromatic solution
Normalized name: ALKALINE AROMATIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic solution (lavender and ginger oil) applied as a mouth spray at 0, 2, 4, 6, and 8 hours postoperatively
Study: 39644858
Drug: Placebo mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouth spray
Study: 39644907
Drug: Mitapivat 50
Normalized name: mitapivat 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitapivat 50 mg
Study: 39644907
Drug: Mitapivat 100
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitapivat 100 mg
Study: 39645270
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of β-blocker therapy
Study: 39647494
Drug: MenABCWY (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY (two doses at months 0 and 6)
Study: 39647494
Drug: 4CMenB (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB (two doses at months 0 and 6)
Study: 39647494
Drug: MenACWY-CRM (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (one dose at month 0)
Study: 39647798
Drug: Placebo (standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard-of-care antibiotics)
Study: 39648079
Drug: Chef-ID intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chef-ID intervention (12-week program including weekly group sessions for cooking skills, nutrition education, and exercise)
Study: 39648217
Drug: Anlotinib plus
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib plus chemotherapy
Study: 39648614
Drug: Islatravir 60
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 60 mg single oral dose
Study: 39648614
Drug: Standard methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methadone therapy
Study: 39648796
Drug: Daily chicken
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chicken egg intake for 6 months
Study: 39649135
Drug: CD40.HIVRI.Env (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD40.HIVRI.Env (0.3, 1.0, or 3.0 mg) alone or co-administered with DNA-HIV-PT123
Study: 39651334
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) therapy
Study: 39651791
Drug: Blinatumomab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab plus chemotherapy (average relapse risk)
Study: 39651791
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (average relapse risk)
Study: 39651791
Drug: Blinatumomab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab plus chemotherapy (high relapse risk)
Study: 39651791
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (high relapse risk)
Study: 39651882
Drug: BRII-693 (10-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRII-693 (10-400 mg single dose)
Study: 39651882
Drug: BRII-693 (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRII-693 (100-200 mg 7-day repeat dose)
Study: 39651882
Drug: BRII-693 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRII-693 (150 mg 14-day repeat dose)
Study: 39651931
Drug: 23ME-00610 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23ME-00610 (2 mg initially, then 1400 mg Q3W)
Study: 39651931
Drug: 23ME-00610 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23ME-00610 (doses ≥ 60 mg)
Study: 39652211
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at acupoints LI4, SJ6, ST36, and ST37, administered twice daily from the day of surgery until the fourth day after the operation
Study: 39652211
Drug: Sham-electroacupuncture (SA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-electroacupuncture (SA), administered twice daily from the day of surgery until the fourth day after the operation
Study: 39652826
Drug: Intravenous daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous daratumumab 16 mg/kg (Long intense)
Study: 39652826
Drug: Intravenous daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous daratumumab 16 mg/kg (Intermediate)
Study: 39652826
Drug: Intravenous daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous daratumumab 16 mg/kg (Short intense)
Study: 39652866
Drug: Usual physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual physiotherapy (control group) consisting of protocolized breathing exercises (8 times daily for 10 minutes) and physical exercises (2 times daily for 10 minutes)
Study: 39653044
Drug: Tezepelumab 420
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 420 mg subcutaneously every 4 weeks for up to 52 weeks
Study: 39653116
Drug: HBI0101 anti-BCMA
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBI0101 anti-BCMA CART therapy, infused with 800 × 10 after lymphodepletion
Study: 39653116
Drug: HBI0101 anti-BCMA
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBI0101 anti-BCMA CART therapy
Study: 39653325
Drug: Mavacamten treatment
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mavacamten treatment
Study: 39653554
Drug: Neoadjuvant PD-1
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant PD-1 inhibitors in combination with chemotherapy
Study: 39653573
Drug: Tailor-made nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailor-made nutrition therapy consisting of oral nutritional supplements and supplementary parenteral nutrition for 10 days
Study: 39653676
Drug: Oral tenofovir-based
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir-based PrEP with point-of-care urine tenofovir testing and adherence counselling
Study: 39654273
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (alteplase 0.90 mg/kg or conservative management)
Study: 39654356
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A, administered every 12 weeks, 155 units total
Study: 39654356
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered every 12 weeks
Study: 39654645
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PNS and Transcutaneous Electrical Nerve Stimulation (TENS)
Study: 39655211
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy Skills Groups (DBT-SG)
Study: 39655786
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (mandatory transfusion at hemoglobin level ≤10 g/dL)
Study: 39655786
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (optional transfusion at hemoglobin level ≤8 g/dL)
Study: 39655790
Drug: CD68-ET3-LV-transduced autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD68-ET3-LV-transduced autologous CD34+ HSCs at doses of 5.0×10
Study: 39656268
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (losartan and irbesartan)
Study: 39656600
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg, intravenously) on Day 1 combined with XELOX (oxaliplatin at 130 mg/m2 and capecitabine)
Study: 39656628
Drug: Runcaciguat (30-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runcaciguat (30-120 mg once daily, titrated weekly)
Study: 39656933
Drug: Fluorometholone 0.1%
Normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorometholone 0.1% eye drops twice daily for 4 weeks
Study: 39656933
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops twice daily for 4 weeks
Study: 39656951
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus ET
Study: 39657224
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen strategy (12-15 L of oxygen per minute or fraction of inspired oxygen of 0.6-1.0)
Study: 39657575
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus letrozole (palbociclib 125 mg on days 1-21 and letrozole 2.5 mg on days 1-28)
Study: 39657575
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus letrozole (placebo on days 1-21 and letrozole 2.5 mg on days 1-28)
Study: 39657693
Drug: Contemporary antiretroviral
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contemporary antiretroviral therapy (ART)
Study: 39658277
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) administration in high-risk pregnancies
Study: 39658277
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (previous study comparison group)
Study: 39658608
Drug: Alternating modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating modified CAPOX (capecitabine 1000 mg/m² and oxaliplatin) plus bevacizumab (anti-VEGF-A antibody)
Study: 39658608
Drug: Alternating modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody)
Study: 39658784
Drug: Tailored internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored internet-delivered cognitive behavior therapy (ICBT) for 10 weeks
Study: 39660140
Drug: Personalized peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized peptide vaccine
Study: 39660637
Drug: Mepolizumab (anti-interleukin-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (anti-interleukin-5 monoclonal antibody)
Study: 39660994
Drug: FHD-609 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHD-609 (5 to 80 mg BIW; n=40)
Study: 39660994
Drug: FHD-609 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHD-609 (40 to 120 mg QW; n=15)
Study: 39661964
Drug: Inhaled long-acting
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled long-acting beta-2 agonists (LABAs)
Study: 39661964
Drug: Short-acting beta-2
Normalized name: HUMAN INTERFERON BETA-2
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta-2 agonists (SABAs)
Study: 39662304
Drug: CIT (5.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT (5.3 g of CIT)
Study: 39662304
Drug: CMA (5.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMA (5.3 g of CIT, 2.7 g of malate)
Study: 39662676
Drug: Complementary food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary food supplements (CFSs) with caregiver nutrition counseling
Study: 39663378
Drug: Seltorexant 40
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seltorexant 40 mg
Study: 39664752
Drug: Oxaloacetate (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaloacetate (2,000 mg per day)
Study: 39665235
Drug: ACM-001.1 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACM-001.1 15 mg
Study: 39665235
Drug: Pindolol 20
Normalized name: pindolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 20 mg twice-daily
Study: 39665235
Drug: ACM-001.1 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACM-001.1 5, 10 or 15 mg twice-daily for 4 days
Study: 39665378
Drug: Implementation strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation strategies (e.g. educational materials, educational meetings, education outreach visits)
Study: 39665585
Drug: Guideline-concordant care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-concordant care (surgery with or without radiation therapy; n=473)
Study: 39665652
Drug: Bedaquiline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline monotherapy for 8 weeks
Study: 39665652
Drug: Standard multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multidrug therapy (as defined by the World Health Organization) after 8 weeks of bedaquiline
Study: 39755168
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of a 21-day cycle
Study: 39666143
Drug: Eptinezumab treatment
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab treatment
Study: 39666256
Drug: Correct DOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correct DOAC dosing predictors
Study: 39666490
Drug: One-to-one music
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-to-one music therapy (MT) intervention for 16 weeks
Study: 39666578
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline nasal irrigation and gargling (HSNIG) with a 2.6% hypertonic saline solution.
Study: 39666984
Drug: Highly effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly effective modulator therapy
Study: 39666985
Drug: lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: lupus anticoagulant
Study: 39666985
Drug: lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: lupus anticoagulant positivity with aD1 and antiphosphatidylserine-prothrombin IgG
Study: 39667379
Drug: PGT121.414.LS 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 3 mg/kg intravenous
Study: 39667379
Drug: PGT121.414.LS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 10 mg/kg intravenous
Study: 39667379
Drug: PGT121.414.LS 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 30 mg/kg intravenous
Study: 39667379
Drug: PGT121.414.LS 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 5 mg/kg subcutaneous
Study: 39667379
Drug: PGT121.414.LS 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 20 mg/kg intravenous plus VRC07-523LS 20 mg/kg
Study: 39667379
Drug: PGT121.414.LS 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 5 mg/kg subcutaneous plus VRC07-523LS 5 mg/kg
Study: 39667379
Drug: PGT121.414.LS (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS (all doses)
Study: 39667379
Drug: PGT121.414.LS (subcutaneous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS (subcutaneous)
Study: 39667379
Drug: PGT121.414.LS and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS and VRC07-523LS (higher-dose and dual combination intravenous)
Study: 39667975
Drug: BAY 81-8973
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 81-8973 (25-50 IU/kg) at least twice weekly
Study: 39668137
Drug: Nonplatinum chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonplatinum chemotherapy (physician's choice of pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan)
Study: 39668364
Drug: Traditional movement
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional movement therapy
Study: 39669115
Drug: Flat flexible
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat flexible footwear (FFF) added to exercise therapy
Study: 39669115
Drug: Stable supportive
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable supportive shoes (SSS) added to exercise therapy
Study: 39669652
Drug: Mild autonomous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild autonomous cortisol secretion (MACS) group (1 mg-DST > 1.8 µg/dL)
Study: 39669652
Drug: Non-functioning adrenal
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-functioning adrenal tumor group (1 mg-DST ≤ 1.8 µg/dL)
Study: 39670007
Drug: Imprime PGG
Normalized name: Imprime PGG
DrugBank: Odetiglucan (DB17468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imprime PGG (4 mg/kg)
Study: 39670468
Drug: Bavdegalutamide (ARV-110)
Normalized name: Bavdegalutamide
DrugBank: Bavdegalutamide (DB19032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavdegalutamide (ARV-110) in combination with abiraterone
Study: 39671024
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) intake (60 g of maltodextrin + fructose)
Study: 39671157
Drug: Metformin extended
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin extended release up to 750 mg twice daily
Study: 39671157
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of metformin and LRFM
Study: 39671174
Drug: Stable gp120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable gp120 vaccine with GLA-SE adjuvant
Study: 39671174
Drug: Transient gp120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transient gp120 vaccine with GLA-SE adjuvant
Study: 39671266
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (control)
Study: 39671525
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural steroid injection + dry needling
Study: 39671525
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural steroid injection + sham dry needling
Study: 39671525
Drug: Only interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only interlaminar epidural steroid injection
Study: 39671543
Drug: Nicotinamide (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (1,500 mg twice a day for 48 weeks)
Study: 39671573
Drug: Active iTBS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active iTBS intervention (intermittent theta burst stimulation), performed daily, 5 days a week, for 2 weeks.
Study: 39671752
Drug: CLR 131
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLR 131 with external beam radiation therapy (EBRT)
Study: 39671779
Drug: Early decrease
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early decrease of circulating tumor DNA (ctDNA) ratio after one cycle of neoadjuvant chemotherapy (NACT)
Study: 39672183
Drug: RH5.1/Matrix-M delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: RH5.1/Matrix-M delayed third-dose regimen
Study: 39672183
Drug: RH5.1/Matrix-M monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: RH5.1/Matrix-M monthly regimen
Study: 39672515
Drug: Moderately hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypofractionated intensity modulated proton therapy (IMPT) with 67.5 Gy to prostate/seminal vesicles and 45 Gy to pelvic lymph nodes in 25 daily fractions, all received androgen deprivation therapy.
Study: 39672984
Drug: Medically tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medically tailored meals (MTM) with medical nutrition therapy (MNT) - home delivery of 12 medically tailored frozen meals and a fresh produce bag weekly for 3 months, plus monthly calls with a registered dietitian for 6 months.
Study: 39672984
Drug: Medically tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medically tailored meals (MTM) with medical nutrition therapy (MNT)
Study: 39673171
Drug: High-dose denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-dose denosumab (120 mg/month with loading doses on weeks 2 and 3) for 6 months
Study: 39673171
Drug: Moderate-dose denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Moderate-dose denosumab (120 mg/3 months)
Study: 39673298
Drug: Daily coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily coffee consumption (>5 cups/day)
Study: 39673298
Drug: Daily coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily coffee consumption (<1 cup/day)
Study: 39673334
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy, 2.5 mg subcutaneous injections daily from Day 1 of ovarian stimulation until oocyte retrieval
Study: 39673334
Drug: Standard ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ovarian stimulation without adjuvant therapy (Control)
Study: 39673415
Drug: Guselkumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 400 mg intravenous infusion at Weeks 0, 4, and 8, followed by 200 mg subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.
Study: 39673415
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion at Weeks 0, 4, and 8, followed by placebo subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.